ProShare Advisors’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.19M | Sell |
14,542
-1,428
| -9% | -$103K | ﹤0.01% | 758 |
|
|
2026
Q1 | $1.09M | Sell |
15,970
-2,719
| -15% | -$193K | ﹤0.01% | 773 |
|
|
2025
Q4 | $1.42M | Buy |
18,689
+2,569
| +16% | +$187K | ﹤0.01% | 745 |
|
|
2025
Q3 | $989K | Sell |
16,120
-2,778
| -15% | -$145K | ﹤0.01% | 813 |
|
|
2025
Q2 | $923K | Sell |
18,898
-1,149
| -6% | -$54.5K | ﹤0.01% | 851 |
|
|
2025
Q1 | $1.02M | Sell |
20,047
-5,055
| -20% | -$252K | ﹤0.01% | 806 |
|
|
2024
Q4 | $1.13M | Buy |
25,102
+6,164
| +33% | +$264K | ﹤0.01% | 861 |
|
|
2024
Q3 | $703K | Buy |
18,938
+4,551
| +32% | +$152K | ﹤0.01% | 944 |
|
|
2024
Q2 | $440K | Sell |
14,387
-3,926
| -21% | -$127K | ﹤0.01% | 1047 |
|
|
2024
Q1 | $533K | Buy |
18,313
+1,564
| +9% | +$43.8K | ﹤0.01% | 1041 |
|
|
2023
Q4 | $462K | Buy |
16,749
+2,616
| +19% | +$59.8K | ﹤0.01% | 1087 |
|
|
2023
Q3 | $317K | Buy |
14,133
+119
| +0.8% | +$4.43K | ﹤0.01% | 1176 |
|
|
2023
Q2 | $570K | Buy |
14,014
+629
| +5% | +$30.8K | ﹤0.01% | 895 |
|
|
2023
Q1 | $648K | Sell |
13,385
-1,599
| -11% | -$73.1K | ﹤0.01% | 823 |
|
|
2022
Q4 | $572K | Buy |
14,984
+1,221
| +9% | +$50.8K | ﹤0.01% | 901 |
|
|
2022
Q3 | $691K | Buy |
13,763
+314
| +2% | +$15.4K | ﹤0.01% | 803 |
|
|
2022
Q2 | $539K | Sell |
13,449
-6,959
| -34% | -$244K | ﹤0.01% | 917 |
|
|
2022
Q1 | $762K | Sell |
20,408
-4,721
| -19% | -$182K | ﹤0.01% | 1038 |
|
|
2021
Q4 | $1M | Buy |
25,129
+1,140
| +5% | +$43.6K | ﹤0.01% | 1016 |
|
|
2021
Q3 | $893K | Sell |
23,989
-6,689
| -22% | -$275K | ﹤0.01% | 942 |
|
|
2021
Q2 | $1.3M | Buy |
30,678
+4,440
| +17% | +$190K | ﹤0.01% | 892 |
|
|
2021
Q1 | $1.24M | Buy |
26,238
+2,020
| +8% | +$120K | ﹤0.01% | 875 |
|
|
2020
Q4 | $1.48M | Buy |
24,218
+5,731
| +31% | +$338K | 0.01% | 726 |
|
|
2020
Q3 | $864K | Buy |
18,487
+41
| +0.2% | +$2.02K | ﹤0.01% | 766 |
|
|
2020
Q2 | $936K | Buy |
18,446
+6,413
| +53% | +$315K | 0.01% | 731 |
|
|
2020
Q1 | $537K | Sell |
12,033
-9,484
| -44% | -$478K | ﹤0.01% | 721 |
|
|
2019
Q4 | $1.03M | Sell |
21,517
-958
| -4% | -$40.7K | ﹤0.01% | 789 |
|
|
2019
Q3 | $760K | Sell |
22,475
-36
| -0.2% | -$1.57K | ﹤0.01% | 847 |
|
|
2019
Q2 | $1.01M | Sell |
22,511
-2,556
| -10% | -$101K | 0.01% | 750 |
|
|
2019
Q1 | $944K | Buy |
25,067
+3,213
| +15% | +$108K | 0.01% | 783 |
|
|
2018
Q4 | $750K | Sell |
21,854
-4,180
| -16% | -$150K | 0.01% | 795 |
|
|
2018
Q3 | $1.22M | Buy |
26,034
+550
| +2% | +$22.8K | 0.01% | 739 |
|
|
2018
Q2 | $860K | Buy |
25,484
+1,177
| +5% | +$36.7K | 0.01% | 888 |
|
|
2018
Q1 | $658K | Sell |
24,307
-3,999
| -14% | -$101K | ﹤0.01% | 987 |
|
|
2017
Q4 | $472K | Buy |
28,306
+2,237
| +9% | +$37.9K | ﹤0.01% | 1162 |
|
|
2017
Q3 | $522K | Buy |
26,069
+1,954
| +8% | +$38.3K | ﹤0.01% | 946 |
|
|
2017
Q2 | $442K | Buy |
24,115
+1,970
| +9% | +$26.5K | ﹤0.01% | 1000 |
|
|
2017
Q1 | $218K | Sell |
22,145
-5,870
| -21% | -$71.1K | ﹤0.01% | 1410 |
|
|
2016
Q4 | $306K | Buy |
28,015
+3,129
| +13% | +$32.8K | ﹤0.01% | 1349 |
|
|
2016
Q3 | $349K | Sell |
24,886
-4,687
| -16% | -$38.1K | ﹤0.01% | 1093 |
|
|
2016
Q2 | $208K | Buy |
29,573
+243
| +0.8% | +$1.78K | ﹤0.01% | 1399 |
|
|
2016
Q1 | $189K | Sell |
29,330
-3,160
| -10% | -$54.8K | ﹤0.01% | 1436 |
|
|
2015
Q4 | $1.05M | Buy |
32,490
+3,122
| +11% | +$91.9K | 0.01% | 713 |
|
|
2015
Q3 | $784K | Sell |
29,368
-1,949
| -6% | -$83.4K | 0.01% | 760 |
|
|
2015
Q2 | $1.51M | Sell |
31,317
-474
| -1% | -$27.7K | 0.02% | 608 |
|
|
2015
Q1 | $1.93M | Buy |
31,791
+4,304
| +16% | +$263K | 0.02% | 571 |
|
|
2014
Q4 | $1.42M | Buy |
27,487
+3,183
| +13% | +$140K | 0.02% | 691 |
|
|
2014
Q3 | $1.07M | Sell |
24,304
-4,759
| -16% | -$149K | 0.01% | 1050 |
|
|
2014
Q2 | $760K | Sell |
29,063
-4,925
| -14% | -$105K | 0.01% | 1318 |
|
|
2014
Q1 | $888K | Buy |
33,988
+22,344
| +192% | +$600K | 0.01% | 1400 |
|
|
2013
Q4 | $198K | Buy |
+11,644
| New | +$205K | ﹤0.01% | 1259 |
|
Other funds holding PTCT
RI
JT
ProShare Advisors's PTCT Position: Q2 2026 in Review
ProShare Advisors reduced its PTC Therapeutics (PTCT) stake by 8.9% in Q2 2026, selling an estimated $103K and leaving 14,542 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #758.
ProShare Advisors first reported a position in PTCT in Q4 2013 and has held it in 51 quarters since. The position peaked at $1.93M in Q1 2015. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- ProShare Advisors held 14,542 shares of PTC Therapeutics worth $1.19M as of Q2 2026.
- ProShare Advisors sold 1,428 PTC Therapeutics shares in Q2 2026, an estimated $103K.
- PTC Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #758 holding.
- ProShare Advisors first reported a position in PTC Therapeutics in Q4 2013 and has held it in 51 quarters since.
- ProShare Advisors's PTC Therapeutics position peaked at $1.93M in Q1 2015.
- 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.